Cellosaurus logo
expasy logo

Cellosaurus CHP-100L (CVCL_IV94)

[Text version]
Cell line name CHP-100L
Synonyms CHP-100-L; CHP100L; CHP-100 Large
Accession CVCL_IV94
Resource Identification Initiative To cite this cell line use: CHP-100L (RRID:CVCL_IV94)
Comments Problematic cell line: Misclassified. Parent cell line (CHP-100) was originally thought to originate from a neuroblastoma but was later shown to be from an Ewing sarcoma.
Part of: MD Anderson Cell Lines Project.
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00610.
Doubling time: 21 hours (PubMed=6825097).
Omics: Protein expression by reverse-phase protein arrays.
Derived from site: In situ; Bone, spine, epidural space; UBERON=UBERON_0003691.
Sequence variations
  • Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=25010205).
  • Mutation; HGNC; 11998; TP53; Simple; p.His233fs (c.696_697ins4); Zygosity=Unspecified (PubMed=25010205).
Disease Ewing sarcoma (NCIt: C4817)
Ewing sarcoma (ORDO: Orphanet_319)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_7166 (CHP-100)
Sex of cell Female
Age at sampling 12Y
Category Cancer cell line
STR profile Source(s): PubMed=25010205; PubMed=33460449

Markers:
AmelogeninX
CSF1PO12,13
D2S133818,21
D3S135816
D5S81811,12
D7S8209,10
D8S117912,15
D13S31711,13
D16S53910
D18S5112,17
D19S43313
D21S1129
TH016,9.3
TPOX8,9
vWA17,19

Run an STR similarity search on this cell line
Web pages https://tcpaportal.org/mclp/
https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
Publications

PubMed=6825097
Bernal S.D., Thompson R., Gilbert F., Baylin S.B.
In vitro and in vivo growth characteristics of two different cell populations in an established line of human neuroblastoma.
Cancer Res. 43:1256-1260(1983)

PubMed=25010205; DOI=10.1371/journal.pgen.1004475
Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S., Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y., Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H., Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S., Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.
The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation.
PLoS Genet. 10:E1004475-E1004475(2014)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=33460449; DOI=10.1002/ijc.33474
Dirks W.G., Capes-Davis A., Eberth S., Fahnrich S., Wilting J., Nagel S., Steenpass L., Becker J.
Cross-contamination meets misclassification: awakening of CHP-100 from sleeping beauty sleep -- a reviewed model for Ewing's sarcoma.
Int. J. Cancer 148:2608-2613(2021)

Cross-references
Encyclopedic resources Wikidata; Q54813261
Polymorphism and mutation databases Cosmic; 2228221
Entry history
Entry creation03-Mar-2017
Last entry update29-Jun-2023
Version number10